David E Gyorki Mbbs,, Fracs

List of Publications by Year
in descending order

89 papers	4,587 citations	236925 25 h-index	106344 65 g-index
90 all docs	90 docs citations	90 times ranked	8879 citing authors

#	Article	IF	Citations
1	Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors. Australasian Journal of Dermatology, 2022, 63, 43-52.	0.7	3
2	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 2022, 54, 6-19.	0.6	3
3	Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. Medical Journal of Australia, 2022, 217, 208-209.	1.7	3
4	Characterization of the treatment-naive immune microenvironment in melanoma with BRAF mutation. , 2022, 10, e004095.		7
5	Spoiled for Choice: Do We Finally Have Clarity on Optimal Treatment Sequencing for Patients with Metastatic Melanoma Harboring an Actionable BRAF Mutation?. Annals of Surgical Oncology, 2022, , .	1.5	0
6	Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (<scp>MelCOR</scp>): A modified Delphi study. Australasian Journal of Dermatology, 2022, , .	0.7	2
7	Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment. , 2022, 10, e004574.		6
8	Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study. The Lancet Global Health, 2022, 10, e1003-e1011.	6.3	15
9	Retroperitoneal and Mesenteric Liposarcomas. Surgical Oncology Clinics of North America, 2022, 31, 399-417.	1.5	0
10	Extent of ulceration in cutaneous melanoma: is this biomarker ready for primetime?. British Journal of Dermatology, 2021, 184, 192-193.	1.5	0
11	Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. Australasian Journal of Dermatology, 2021, 62, 168-176.	0.7	3
12	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. Journal of the American College of Surgeons, 2021, 232, 424-431.	0.5	14
13	The role of ¹⁸Fâ€FDG PET/CT in retroperitoneal sarcomasâ€”A multicenter retrospective study. Journal of Surgical Oncology, 2021, 123, 1081-1087.	1.7	23
14	Generating CAR T cells from tumor-infiltrating lymphocytes. , 2021, 9, 251513552110171.	2.3	6
15	Desmoplastic melanoma: a review of its pathology and clinical behaviour, and of management recommendations in published guidelines. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1290-1298.	2.4	14
16	Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. Annals of Surgical Oncology, 2021, 28, 6882-6889.	1.5	14
17	Active surveillance of patients who have sentinel node positive melanoma: An international, multiâ€institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLTâ€2). Cancer, 2021, 127, 2251-2261.	4.1	37
18	Ptpn2 and KLRG1 regulate the generation and function of tissue-resident memory CD8+ T cells in skin. Journal of Experimental Medicine, 2021, 218, .	8.5	12

#	Article	IF	Citations
19	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Annals of Surgical Oncology, 2021, 28, 7873-7888.	1.5	105
20	Second-line immunotherapy in patients with metastatic melanoma. Lancet Oncology, The, 2021, 22, 746-748.	10.7	1
21	ASO Author Reflections: Standardization in the Management of Retroperitoneal Sarcoma Through International Collaboration. Annals of Surgical Oncology, 2021, 28, 7889-7890.	1.5	4
22	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. ANZ Journal of Surgery, 2021, 91, 3-13.	0.7	7
23	Tumor reactivity of CD8⁺ T cells favors acquisition of dysfunctional states in human melanoma. Immunology and Cell Biology, 2021, 99, 914-916.	2.3	0
24	Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries. Lancet, The, 2021, 397, 387-397.	13.7	125
25	Primary mesenteric sarcomas: Collaborative experience from the Transâ€Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Journal of Surgical Oncology, 2021, 123, 1057-1066.	1.7	3
26	Management of Retroperitoneal Sarcomas. , 2021, , 309-322.		1
27	Letter Regarding Editorial by Samuel Zagarella. American Journal of Dermatopathology, 2021, 43, 539-541.	0.6	2
28	Skin colonization with beta papilloma virus drives tissue immunity and resistance to squamous cell cancer. Immunology and Cell Biology, 2020, 98, 9-11.	2.3	5
29	Malignant transformation of an ileostomy stoma scar: an unusual presentation. ANZ Journal of Surgery, 2020, 90, 1770-1772.	0.7	0
30	Cutaneous leiomyosarcoma: dermal and subcutaneous. Australasian Journal of Dermatology, 2020, 61, 243-249.	0.7	10
31	Patient-reported outcomes in melanoma survivors at 1, 3 and 5Âyears post-diagnosis: a population-based cross-sectional study. Quality of Life Research, 2020, 29, 2021-2027.	3.1	11
32	Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. BMJ Open, 2020, 10, e032636.	1.9	6
33	Correlation between percutaneous biopsy and final histopathology for retroperitoneal sarcoma: a singleâ€centre study. ANZ Journal of Surgery, 2020, 90, 497-502.	0.7	14
34	Management of pleomorphic dermal sarcoma. ANZ Journal of Surgery, 2020, 90, 2322-2324.	0.7	22
35	Systemic Therapy for Melanoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 3947-3970.	1.6	190
36	Australian general practitionersâ€™ attitudes and knowledge of sentinel lymph node biopsy in melanoma management. Australian Journal of General Practice, 2020, 49, 355-362.	0.8	3

#	Article	IF	Citations
37	Diagnosis and management of cutaneous melanoma. Australian Journal of General Practice, 2020, 49, 733-739.	0.8	8
38	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
39	Characterizing high-grade serous papillary carcinoma of tunica vaginalis. Urology Case Reports, 2019, 26, 100949.	0.3	1
40	An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?. Melanoma Management, 2019, 6, MMT24.	0.5	4
41	The Prognosis and Natural History of In-Transit Melanoma Metastases at a High-Volume Centre. Annals of Surgical Oncology, 2019, 26, 4673-4680.	1.5	6
42	ASO Author Reflections: The Impacts of a Negative Sentinel Lymph Node on Quality of Life. Annals of Surgical Oncology, 2019, 26, 651-652.	1.5	1
43	Negative Sentinel Lymph Node Biopsy in Patients with Melanoma: The Patientâ€™s Perspective. Annals of Surgical Oncology, 2019, 26, 2263-2267.	1.5	11
44	Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Annals of Oncology, 2019, 30, 804-814.	1.2	117
45	Accumulation of CD103⁺ CD8⁺ T cells in a cutaneous melanoma micrometastasis. Clinical and Translational Immunology, 2019, 8, e1100.	3.8	8
46	Systemic therapies for unresectable locoregional melanoma: a significant area of need. Melanoma Management, 2019, 6, MMT25.	0.5	6
47	Locoregional melanoma: identifying optimal care in a rapidly changing landscape. Melanoma Management, 2019, 6, MMT22.	0.5	0
48	Tissue-resident memory CD8+ T cells promote melanomaâ€“immune equilibrium in skin. Nature, 2019, 565, 366-371.	27.8	266
49	Management of inâ€transit melanoma metastases: a review. ANZ Journal of Surgery, 2019, 89, 647-652.	0.7	18
50	Ectopic breast cancer in the inguinal region. Breast Journal, 2019, 25, 155-156.	1.0	3
51	Restricted venous access after lymph node dissection: no evidence (voodoo). ANZ Journal of Surgery, 2018, 88, 131-132.	0.7	0
52	Systematic Review of Clinical Outcomes Following Various Treatment Options for Patients with Extraabdominal Desmoid Tumors. Annals of Surgical Oncology, 2018, 25, 1544-1554.	1.5	31
53	Melanoma in the very elderly, management in patients 85 years of age and over. Journal of Geriatric Oncology, 2018, 9, 488-493.	1.0	11
54	Preoperative Positron Emission Tomography for Node-Positive Head and Neck Cutaneous Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2018, 158, 122-126.	1.9	14

#	Article	IF	Citations
55	Importance of preoperative diagnosis for management of patients with suspected retroperitoneal sarcoma. ANZ Journal of Surgery, 2018, 88, 274-277.	0.7	6
56	Management of In-Transit Melanoma: We Need Some High-Quality Data. Journal of Oncology Practice, 2018, 14, 302-303.	2.5	1
57	Treatment of patients with primary retroperitoneal sarcoma: predictors of outcome from an Australian specialist sarcoma centre. ANZ Journal of Surgery, 2018, 88, 1151-1157.	0.7	10
58	Incidental Metastatic Melanoma Identified on 68Gaâ€“Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2018, 43, 509-511.	1.3	8
59	1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. Annals of Surgical Oncology, 2018, 25, 2541-2549.	1.5	35
60	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature Medicine, 2018, 24, 986-993.	30.7	689
61	Prognostic markers in metastatic cutaneous squamous cell carcinoma of the head and neck. Head and Neck, 2017, 39, 772-778.	2.0	33
62	When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the â€˜Australian guidelines for the management of cutaneous melanomaâ€™. Australasian Journal of Dermatology, 2017, 58, 274-277.	0.7	12
63	Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma. Melanoma Research, 2017, 27, 43-49.	1.2	13
64	Surgical referral coordination from a first-level hospital: a prospective case study from rural Nepal. BMC Health Services Research, 2017, 17, 676.	2.2	8
65	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-14.	3.0	51
66	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation, 2017, 127, 929-941.	8.2	251
67	Intralesional PVâ€10 for inâ€transit melanomaâ€”A singleâ€center experience. Journal of Surgical Oncology, 2016, 114, 380-384.	1.7	19
68	Excision margins and sentinel lymph node status as prognostic factors in thick melanoma of the head and neck: A retrospective analysis. Head and Neck, 2016, 38, 1373-1379.	2.0	10
69	A prospective study comparing digital breast tomosynthesis with digital mammography in surveillance after breast cancer treatment. European Journal of Cancer, 2016, 61, 122-127.	2.8	25
70	A community-based model of rapid autopsy in end-stage cancer patients. Nature Biotechnology, 2016, 34, 1010-1014.	17.5	66
71	Recent Insights and Advances in the Management of Merkel Cell Carcinoma. Journal of Oncology Practice, 2016, 12, 637-646.	2.5	30
72	CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. Cancer Research, 2016, 76, 3965-3977.	0.9	26

#	Article	IF	Citations
73	Sentinel Lymph Node Biopsy in T4 Melanoma: An Important Risk-Stratification Tool. Annals of Surgical Oncology, 2016, 23, 579-584.	1.5	27
74	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Seminars in Immunology, 2016, 28, 64-72.	5.6	52
75	Postâ€operative survival following metastasectomy for patients receiving BRAF inhibitor therapy is associated with duration of preâ€operative treatment and elective indication. Journal of Surgical Oncology, 2015, 111, 980-984.	1.7	24
76	Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. Current Anesthesiology Reports, 2015, 5, 257-267.	2.0	0
77	Sentinel lymph node biopsy for melanoma: an important riskâ€stratification tool. Medical Journal of Australia, 2015, 202, 79-79.	1.7	2
78	Management of recurrent retroperitoneal sarcoma. Journal of Surgical Oncology, 2014, 109, 53-59.	1.7	48
79	Current management of advanced melanoma: a transformed landscape. ANZ Journal of Surgery, 2014, 84, 612-617.	0.7	13
80	Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma. Annals of Surgical Oncology, 2013, 20, 3106-3111.	1.5	47
81	Improving the impact of didactic resident training with online spaced education. ANZ Journal of Surgery, 2013, 83, 477-480.	0.7	20
82	Prophylactic Central Neck Dissection in Differentiated Thyroid Cancer: An Assessment of the Evidence. Annals of Surgical Oncology, 2013, 20, 2285-2289.	1.5	61
83	The delicate balance of melanoma immunotherapy. Clinical and Translational Immunology, 2013, 2, e5.	3.8	22
84	Endoscopic management of post-cholecystectomy biliary fistula. Hpb, 2011, 13, 699-705.	0.3	12
85	Gata-3 Negatively Regulates the Tumor-Initiating Capacity of Mammary Luminal Progenitor Cells and Targets the Putative Tumor Suppressor Caspase-14. Molecular and Cellular Biology, 2011, 31, 4609-4622.	2.3	96
86	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine, 2009, 15, 907-913.	30.7	1,261
87	Desmoplastic Melanoma: A Pathologically and Clinically Distinct Form of Cutaneous Melanoma. Annals of Surgical Oncology, 2005, 12, 207-213.	1.5	140
88	Concurrent adjuvant radiotherapy and interferon-Î±2b for resected high risk stage III melanoma â€“ a retrospective single centre study. Melanoma Research, 2004, 14, 223-230.	1.2	27
89	Sentinel Lymph Node Biopsy for Patients With Cutaneous Desmoplastic Melanoma. Annals of Surgical Oncology, 2003, 10, 403-407.	1.5	94